Gestational Trophoblastic Disorders: An Update in 2015
- PMID: 26556906
- PMCID: PMC4629994
- DOI: 10.1055/s-0035-1558054
Gestational Trophoblastic Disorders: An Update in 2015
Abstract
Gestational trophoblastic diseases (GTD) are a group of pregnancy-related disorders representing rare human tumours. They encompass premalignant disorders including complete (CHM), partial hydatidiform mole (PHM), exaggerated placental site (EPS), and placental-site nodule (PSN) as well as malignant disorders (also known as "gestational trophoblastic neoplasia [GTN]") including invasive mole, choriocarcinoma (CC), placenta-site trophoblastic tumour (PSTT), and epitheloid trophoblastic tumours (ETT) (Fig. 1). Originally, GTD develop from abnormal proliferation of trophoblastic tissue and form botryoid arranged vesicles. Premalignant moles are usually treated by suction curettage while persistent and recurrent moles and malignant forms require systemic therapy with methotrexate or combination chemotherapy consisting of etoposide, actimomycin D, methotrexate, vincristine, and cyclophosphamide (EMA-CO). β-human chorion gonadotropin (β-hCG) plays a crucial role in diagnosis and monitoring therapeutic effects. Since the definitive diagnosis cannot be obtained by histology in most cases, persistent or recurrent disease is diagnosed by elevated or persistent serum levels of β-hCG. While curing rates are described to be as high as 98 %, GTD may initially present, recur, or end up as a metastasising systemic disease. This underlines the importance of a regular and consistent follow-up after treatment.
Gestationsbedingte Trophoblasterkrankungen (GTE) gehören zu der Gruppe seltener menschlicher Tumoren, die im Rahmen einer Schwangerschaft entstehen. Diese Gruppe umfasst prämaligne Veränderungen wie Blasenmole und Partialmole, hyperplastische Implantationsstelle des Plazentabetts (exaggerated placental site, EPS) und Plazentabettknötchen (placental site nodule, PSN) sowie maligne Erkrankungen (auch gestationsbedingte Trophoblastneoplasien [GTN] genannt) wie invasive Molen, Chorionkarzinom, Plazentabetttumor (placental site trophoblastic tumor, PSTT) und epitheloider Trophoblasttumor (ETT) (Abb. 1). Die Entstehung von GTE ist durch die abnorme Proliferation von Trophoblastzellen gekennzeichnet, die traubenförmig angeordnete Bläschen bilden. Prämaligne Molen werden zumeist mit Saugkürettage therapiert. Die Behandlung persistierender und rezidivierender Molen sowie maligner Formen besteht aus einer systemischen Therapie mit Methotrexat oder einer Kombinationschemotherapie aus Etoposid, Actinomycin-D, Methotrexat, Vincristin, und Cyclophosphamid (EMA-CO). β-humanes Choriongonadotropin (β-hCG) spielt eine wichtige Rolle bei der Diagnose und Kontrolle der Therapie. Da eine histologische Untersuchung in den meisten Fällen keine endgültige Diagnose liefert, beruht die Diagnose von Persistenz und Rezidiv auf erhöhten (persistierenden) Serumkonzentrationen von β-hCG. Obwohl die in der Literatur angegebenen Heilungsraten hoch sind mit bis zu 98 %, können GTE nach dem ersten Auftreten rekurrieren oder in eine systemische Erkrankung mit Metastasierung übergehen. Dies unterstreicht die Bedeutung einer regelmäßigen und konsequenten Nachsorge.
Keywords: gestational neoplasia; gestational trophoblastic disease; human chorion gonadotropin; hydatidiform moles; molar pregnancy.
Conflict of interest statement
Figures







Similar articles
-
Gestational Trophoblastic Disease.2024 Feb 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Feb 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 29261918 Free Books & Documents.
-
A Case of Rapid Transformation from Hydatidiform Mole to Invasive Mole: The Importance of β-hCG (Human Chorionic Gonadotropin) Serum Levels in Follow-Up Evaluation.Am J Case Rep. 2021 Jun 15;22:e931156. doi: 10.12659/AJCR.931156. Am J Case Rep. 2021. PMID: 34127641 Free PMC article.
-
Surgery including fertility-sparing treatment of GTD.Best Pract Res Clin Obstet Gynaecol. 2021 Jul;74:97-108. doi: 10.1016/j.bpobgyn.2020.10.005. Epub 2020 Oct 10. Best Pract Res Clin Obstet Gynaecol. 2021. PMID: 33127305 Free PMC article. Review.
-
Gestational trophoblastic diseases - clinical guidelines for diagnosis, treatment, follow-up, and counselling.Dan Med J. 2015 Nov;62(11):A5082. Dan Med J. 2015. PMID: 26522484
-
Pathology of gestational trophoblastic disease (GTD).Best Pract Res Clin Obstet Gynaecol. 2021 Jul;74:3-28. doi: 10.1016/j.bpobgyn.2021.02.005. Epub 2021 Mar 31. Best Pract Res Clin Obstet Gynaecol. 2021. PMID: 34219021 Review.
Cited by
-
A tutorial on dynamic risk prediction of a binary outcome based on a longitudinal biomarker.Biom J. 2020 Mar;62(2):398-413. doi: 10.1002/bimj.201900044. Epub 2019 Nov 28. Biom J. 2020. PMID: 31777998 Free PMC article.
-
Invasive mole presenting as a heavily bleeding vaginal lesion 3 weeks after uterine evacuation.BMJ Case Rep. 2021 Jun 21;14(6):e242208. doi: 10.1136/bcr-2021-242208. BMJ Case Rep. 2021. PMID: 34155019 Free PMC article.
-
Human Chorionic Gonadotropin and Early Embryogenesis: Review.Int J Mol Sci. 2022 Jan 26;23(3):1380. doi: 10.3390/ijms23031380. Int J Mol Sci. 2022. PMID: 35163303 Free PMC article. Review.
-
NLRP7 Promotes Choriocarcinoma Growth and Progression through the Establishment of an Immunosuppressive Microenvironment.Cancers (Basel). 2021 Jun 15;13(12):2999. doi: 10.3390/cancers13122999. Cancers (Basel). 2021. PMID: 34203890 Free PMC article.
-
Ultra-high-risk choriocarcinoma with atraumatic splenic rupture: a rare case report.J Int Med Res. 2021 Aug;49(8):3000605211033222. doi: 10.1177/03000605211033222. J Int Med Res. 2021. PMID: 34340579 Free PMC article.
References
-
- Seckl M J, Sebire N J, Berkowitz R S. Gestational trophoblastic disease. Lancet. 2010;376:717–729. - PubMed
-
- Palmer J R. Advances in the epidemiology of gestational trophoblastic disease. J Reprod Med. 1994;39:155–162. - PubMed
-
- Ngan S, Seckl M J. Gestational trophoblastic neoplasia management: an update. Curr Opin Oncol. 2007;19:486–491. - PubMed
-
- Seckl M J, Fisher R A, Salerno G. et al.Choriocarcinoma and partial hydatidiform moles. Lancet. 2000;356:36–39. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials